Sun Pharmaceutical Industries Limited announced the appointment of Kirti Ganorkar as the Managing Director, effective 1 September 2025, for a term of five years, subject to shareholder approval.
Dilip Shanghvi's designation will change to Executive Chairman, effective 1 September 2025. He will continue to chair the Board and focus on strengthening Sun Pharma’s specialty portfolio and long-term strategy.
Kirti Ganorkar, who joined Sun Pharma in 1996, has consistently led the company's India Business since June 2019, growing its market share.
Kirti Ganorkar stated, "Sun Pharma is at an exciting juncture with all its businesses well-positioned for growth. Building on the strong foundation laid by Mr. Shanghvi and ably supported by our global leadership team, I’m confident of continued success of the company.”
Dilip Shanghvi commented, “Kirti has consistently demonstrated effective leadership managing diverse roles at Sun. I have a firm belief in his ability to lead the company into its next phase of growth and extend my best wishes for his success. Kirti’s elevation showcases our strong in-house talent pool, ensuring continuity of Sun’s core value systems.”
Additionally, Abhay Gandhi, President & CEO, North America, will be leaving the company.
Richard ("Rick") Ascroft will join as CEO – North America, succeeding Abhay Gandhi.
Aalok Shanghvi, Whole-time Director and Chief Operating Officer, will additionally oversee the North America business, with Rick reporting to him.